1060 Optimally engineered IL18 Fc-fusion proteins balance potency and pharmacokinetics to promote strong anti-tumor activity
Main Authors: | Christine Bonzon, Rumana Rashid, Irene Leung, Nicole Rodriguez, Alex Nisthal, Ruschelle Love, Sung-Hyung Lee, Panida Lertkiatmongkol, Sher Karki, Kendra N Avery, Norman J Barlow, Seung Y Chu, Gregory L Moore, John R Desjarlais |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
698 PD-L1 targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors
by: Jing Qi, et al.
Published: (2021-11-01) -
564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents
by: Ke Liu, et al.
Published: (2020-11-01) -
Mechanical and Microstructural Properties of Friction Welded AISI 304 Stainless Steel to AISI 1060 Steel AISI 1060
by: Ates H., et al.
Published: (2014-10-01) -
Homology modeling of mosquito cytochrome P450 enzymes involved in pyrethroid metabolism: insights into differences in substrate selectivity
by: Rongnoparut Pornpimol, et al.
Published: (2011-09-01) -
Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc
by: Marissa J.M. Traets, et al.
Published: (2020-10-01)